Lastly, against the background of tumors that have activating EGFR mutations, the LAURA trial, is a phase 3 study which is evaluating the efficacy and safety of osimertinib following CCRT in patients with stage III EGFR mutation-positive NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.